112 Chapter 6 Table 3. Respiratory therapies Pre-AOC Post-AOC P value* High frequency oscillation, n (%) 56 (19.1) 51 (17.3) 0.57 Inhaled nitric oxide, n (%) 31 (10.6) 32 (10.5) 0.92 Dexamethasone, n (%) 27 (9.2) 29 (9.8) 0.80 Surfactant, n (%) 164 (56.0) 147 (49.8) 0.14 via intubation, n (%) 131 (44.7) 76 (25.8) < 0.001 via minimally invasive technique, n (%) 33 (11.3) 71 (24.1) Invasive ventilation days, mean (SD) 6.4 (10.1) 4.7 (8.3) 0.029 CPAP days, mean (SD) 10.8 (11.7) 13.9 (15.2) 0.006 HFNC days, mean (SD) 2.3 (5.4) 5.8 (8.1) < 0.001 Low flow days, mean (SD) 1.5 (3.4) 1.5 (3.2) 0.86 Supplemental oxygen days, mean (SD) 8.0 (13.5) 11.3 (16.9) 0.008 Average inspired oxygen during first week, mean (SD) 25.2 (10.2) 24.8 (8.8) 0.58 during entire admittance, mean (SD) 25.7 (9.8) 25.7 (9.1) 0.93 CPAP, continuous positive airway pressure; HFNC, high flow nasal cannula; Average inspired oxygen (expressed as %) while on respiratory support. *Statistical analysis with independent T-test or chi-square test as appropriate
RkJQdWJsaXNoZXIy MTk4NDMw